

Research Activities Newsletter

January 2020

In the News: Congratulations to the following awardees!!



Katherine Balantakin, Clinical Assistant Professor of Exercise and Nutrition Sciences, received a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *The Intersection between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement*. The project will explore the relationships between LOC eating, parental restriction, and RRV of HED food with respect to obesity risk in a sample of 7-10 year old children at risk for obesity.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, **Jihnhee Yu**, Associate Professor of Biostatistics, are both CO-I on a new award from Regents of the University of Colorado (PI: Denise Lillvis, Surgery) for the research project entitled, *Examining Factors Associated with Increased Physical Trauma for Children and Youth with Special Health Care Needs*. This project uses national trauma center data to examine associations between CYSHCN status and trauma incident characteristics, injury mechanism/severity, and outcomes such as ICU admission and death.



Kimberly Naus, Director of CAT Client Services, received a continuation award from the New York State Justice Center for the Protection of People with Special Needs for the project entitled, *Technology Related Assistance for Individuals with Disabilities (TRAID) Program*. TRAIID supports the development of state-wide consumer-responsive technical assistance programs for persons with disabilities.

Ms. Naus also received a continuation of an award from the NYS Office of Children and Family Services entitled, *OCFS NYCB Assistive Technology Center Area 1 – Buffalo*. The Center provides services to NYS Commission of the Blind consumers located within the eight counties of Western New York. Services include assessing the technology needs and abilities of participants referred, recommending assistive technology configurations to meet their needs, and providing training to enable the use of their equipment in a work or educational setting.



John Violanti, Research Professor of Epidemiology and Environmental Health, is PI on a new award from the Centers for Disease Control and Prevention for the research project entitled, *A Longitudinal Examination of Mental and Physical Health among Police Associated with COVID-19*. This project will evaluate the impact of COVID-19 on police officers including the longitudinal mental and physical health effects of the COVID-19 pandemic on police officers.

In This Issue

In the News: Congratulations to the Following Awardees	1
Training Opportunities.....	3
Grant Clinic.....	3
NIH Funding Opportunities	
Request for Applications (RFA)	4
Program Announcements Reviews in an Institute (PAR)	7
Program Announcements (PA)	11
Funding Opportunities.....	12
Individual Actions for Sustainability	12

Grant Clinic

[Reminder – Training Opportunity Research Fundamentals at UB](#)

The Office of Research Advancement and Sponsored Projects Services will present the workshop, Research Fundamentals at UB, on January 26, 2021 at 11:00 a.m. This workshop will introduce participants to UB's internal processes involved in submitting proposals, as well as to the support system that is available for faculty developing proposals. While this workshop may be most valuable for early-career faculty, faculty who are new to UB, or who are new to the research proposal submission process, all interested parties - faculty, researchers, postdoc fellows, and support staff – are welcome.

Register here: <https://www.eventbrite.com/e/research-fundamentals-at-ub-tickets-135551230379>

[Reminder – The SPHHP Provides External Reviews](#)

As a reminder, the Dean's Office provides external reviews of grant applications. Obtaining grant funding is difficult these days and an external review can help ensure your application is competitive. External reviews have helped SPHHP researchers to achieve funding. See testimonials at the RAS website, [External Review](#). If you would like request an external review, please complete the form located on the RAS webpage at least 4-5 weeks prior to the submission deadline.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-MD-21-008](#)

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include “NOT-MD-21-008” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2022.

[NOT-TR-21-011](#)

Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease Public Health Needs

The National Center for Advancing Translational Sciences (NCATS) is issuing this notice to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS expects to issue 2-9 awards (anticipated to be \$30,000 to \$60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “NOT-TR-21-011” in box 4B of the SF424 R&R form.** This NOSI will expire on June 02, 2021.

[NOT-CA-21-008](#)

Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

Through funds available from the [Cancer Moonshot Initiative](#), and pursuant to the National Cancer Institute’s (NCI’s) interest in advancing data visualization tools and methods for cancer research, applications are invited, through [PA-20-272](#) in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more exploratory and interpretable by the broader cancer research community. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “PA-20-272” in box 4B of the SF424 R&R form.** Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

FEBRUARY DUE DATES

[RFA-ES-21-001](#) (R01 Clinical Trial Optional)

Outstanding New Environmental Scientist (ONES) Award

The ONES Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on understanding the effects of environmental exposure on people’s health.

Application Due Date: February 26, 2021; February 24, 2022; February 24, 2023

[RFA-CA-20-055 \(K99/R00\)](#) Independent Basic Experimental Studies with Humans Required NCI

[RFA-CA-20-056 \(K99/R00\)](#) Independent Clinical Trial Not Allowed

[RFA-CA-20-057 \(K99/R00\)](#) Independent Clinical Trial Required

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers

The purpose of this program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions.

Application Due Date: February 26, 2021

MARCH DUE DATES

[RFA-CA-20-051 \(R01\)](#) CLINICAL TRIAL REQUIRED

Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science

research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.

Application Due Dates: March 15, 2021; January 18, 2022.

[RFA-HL-22-009](#) (R25 Clinical Trial Not Allowed)

Summer Institute for Research Education in Biostatistics and Data Science

This FOA will support creative educational activities with a primary focus on: **Courses for Skills Development**. For example, advanced courses in a specific discipline or research area, clinical procedures for research, or specialized research techniques. NHLBI and NIAID invite applications for grants to develop, conduct, and evaluate summer courses in the principles and methods of contemporary biostatistics and data science as employed in current biomedical research. The courses will introduce advanced undergraduates, recent graduates, and beginning graduate students to the field of biostatistics and data science for the purpose of attracting new students to the field. NHLBI and NIAID expect that the proposed courses will cover the fundamental concepts of probability, statistical reasoning, data science, and inferential methods motivated, in part, by examples of relevance to NHLBI and NIAID. It is anticipated that the courses will be taught during the summers of 2022, 2023, 2024, 2025, and 2026 with appropriate modifications or refinements over the course of the award.

Application Due Dates: March 08, 2021

[RFA-MH-21-116](#) (R01 Clinical Trial Optional)

[RFA-MH-21-117](#) (R21 Clinical Trial Optional)

Mood Disorders in People Living with HIV: Mechanisms and Pathways

The purpose of this FOA is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Application Due Dates: March 10, 2021

[RFA-AA-21-001](#) (R01 Clinical Trial Optional)

Improving Health Disparities in Alcohol Health Services

This FOA solicits applications on health disparities and health services-related research focusing on: 1.) access to treatment; 2.) making treatment more appealing; 3.) costs; 4.) dissemination and implementation. All Applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.

Application Due Dates: March 15, 2021

MULTIPLE DUE DATES

[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills

in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date. **Application Due Dates:** February 3, 2021, October 22, 2021, and October 21, 2022

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: February 08, 2021, October 08, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: February 08, 2021, October 08, 2021, July 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** April 9, 2021, September 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

Application Due Dates: Monthly due dates; please refer to the RFA.

[RFA-CA-21-013](#) (R21 Clinical Trial Optional)

[RFA-CA-21-014](#) (U01 Clinical Trial Optional)

[RFA-CA-21-015](#) (U24 Clinical Trial Optional)

[RFA-CA-21-016](#) (U24 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

The purpose of FOA is to invite applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined as initial tool development or the significant modification of existing tools for new applications. **Application Due Dates:** June 8, 2021; November 17, 2021

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

Application Due Dates: June 22, 2021; June 22, 2022; June 22, 2023.

[RFA-HL-21-014](#) (R01 – Clinical Trial Optional)

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus

This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan.

Application Due Dates: March 15, 2021; October 15, 2021

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-20-236\(R25\)](#) Clinical Trials Not Allowed

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** March 15, 2021, August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022, March 15, 2023, August 10, 2023, November 15, 2023

[PAR-20-310 \(R01\)](#) Clinical Trial Optional

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged.

Application Due Dates: March 17, 2021; November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023.

[PAR-20-302\(R01\)](#)

[PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA.

Application Due Dates: December 7, 2021; and December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023.

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with [PATH Study objectives](#) and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens.

Application Due Dates: April 30, 2021, October 29, 2021, April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting

areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2021, August 25, 2022, and August 25, 2023.

[PAR-21-046\(G13\)](#) Clinical Trial Not Allowed

NLM Grants for Scholarly Works in Biomedicine and Health

The National Library of Medicine (NLM) awards Grants for Scholarly Works in Biomedicine and Health for the preparation of book-length manuscripts and other works of academic and/or public health policy value to U.S. health professionals, public health officials, biomedical researchers, historians of the health sciences, and scholars of all disciplines working at the intersection of the digital humanities/data science and the history of the health sciences.

Application Due Dates: February 26, 2021

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the [NCI DCTD website](#) and/or the [OHAM website](#) to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research;

Application Due Dates: Standard dates apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see [NOT-OD-15-015](#) for details) and provide specific clinical trial information as described in this FOA and the application instructions.

Application Due Dates: Standard dates apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required)

Stephen I. Katz Early Stage Investigator Research Project Grant

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023

[PAR-21-072](#) (R24 Clinical Trial Not Allowed)

NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research.

Application Due Dates: Standard dates apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase).

Application Due Dates: Standard dates apply

[PAR-20-315](#) R00 Clinical Trial Optional

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Due Dates: Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes.

Application Due Dates: Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.

Application Due Dates: June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials.

Application Due Dates: February 19, 2021, June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAS-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the

HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Application Due Dates: Standard dates apply.

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-21-071](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Expiration Date: May 8, 2023

[PA-20-272](#)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Expiration Date: July 24, 2023

[PA-21-047](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)

[PA-21-048](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

[PA-21-049](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-050](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-051](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

[PA-21-052](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

Expiration Date: September 8, 2023

[PA-21-110](#) Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

Expiration Date: May 08, 2024

OTHER FUNDING OPPORTUNITIES

Department of Defense

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations. The FY21 appropriation is \$150 million (M); however, it is contingent upon the outcome of a pending rescissions request.

[W81XWH-21-BCRP-BTA12](#) Breakthrough Award Levels 1 and 2

Pre-Application Deadline: March 11, 2021; **Application Submission Deadline:** March 25, 2021

[W81XWH-21-BCRP-BTA3](#) Breakthrough Award Level 3

Pre-Application Deadline: March 12, 2021; **Invited Application Submission Deadline:** June 23, 2021

[W81XWH-21-BCRP-BTA4](#) Breakthrough Award Level 4

Pre-Application Deadline: March 12, 2021; **Invited Application Submission Deadline:** June 23, 2021

[W81XWH-21-BCRP-EOHS](#) Era of Hope Scholar Award

Pre-Application Deadline: March 11, 2021; **Application Submission Deadline:** March 25, 2021;

Confidential Letters of Recommendation: March 29, 2021

[W81XWH-21-BCRP-INNOV](#) Innovator Award

Pre-Application Deadline: March 12, 2021; Application Submission Deadline: June 23, 2021;
Confidential Letters of Recommendation: June 25, 2021

[W81XWH-21-BCRP-TBCCA](#) Transformative Breast Cancer Consortium Award

Pre-Application Deadline: March 12, 2021; Invited Application Submission Deadline: June 23, 2021

[Robert Wood Johnson Foundation](#)

Equity-Focused Policy Research: Building Cross-Cutting Evidence on Supports for Families with Young Children

The Equity-Focused Policy Research grant program seeks to fund a body of research that illuminates strategies and policies that enhance families' equitable access to key resources for supporting their children's healthy development. EFPR grants are guided by a research agenda that focuses on: (1) understanding the sources of inequities in families' access to and use of key resources; (2) identifying and testing innovations to advance equity; and (3) strategies for scaling up policies and approaches that are effective in advancing equity.

Brief Proposal Due: February 16, 2021; **Full Proposal Due:** May 11, 2021

Individual Actions for Sustainability

Maintain your ride.

Keep tires properly inflated. A simple tune-up can boost miles per gallon anywhere from 4 percent to 40 percent, and a new air filter can get you a 10 percent boost.



Visit our website for more information at sphhp.buffalo.edu/ras